Gannex Announces Clinical Trial Application of ASC42, an FXR Agonist, for Treatment of Primary Biliary Cholangitis Accepted by China NMPA ...Middle East

SHANGHAI, Sept. 5, 2021 /PRNewswire/ -- Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX:1672) announces today that the clinical trial application of ASC42 to treat patients with primary biliary cholangitis (PBC) has been accepted for review by China National...

Hence then, the article about gannex announces clinical trial application of asc42 an fxr agonist for treatment of primary biliary cholangitis accepted by china nmpa was published today ( Monday 06/09/2021 - 04:30 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Gannex Announces Clinical Trial Application of ASC42, an FXR Agonist, for Treatment of Primary Biliary Cholangitis Accepted by China NMPA )

Also on site :

• 2000s Heavy Metal Band Shares Exciting Music Festival News
• Saudi to Sudan: Can Pakistan expand military footprint across Arab world?
• Iconic '80s Heavy Metal Band Announces 2026 North America Tour Dates